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ABSTRACT
Background Acute respiratory distress syndrome
(ARDS) is a life-threatening condition characterised by
pulmonary oedema, respiratory failure and severe
inﬂammation. ARDS is further characterised by the
recruitment of neutrophils into the lung interstitium and
alveolar space.
Objectives The factors that regulate neutrophil
inﬁltration into the inﬂamed lung and our understanding
of the pathomechanisms in ARDS remain incomplete.
This study aimed at determining the role of the
chemokine (C-C motif ) ligand (CCL)2 and CCL7 in
ARDS.
Methods CCL2 and CCL7 protein levels were
measured in bronchoalveolar lavage (BAL) ﬂuid obtained
from lipopolysaccharide(LPS)-challenged human
volunteers and two separate cohorts of patients with
ARDS. Neutrophil chemotaxis to ARDS BAL ﬂuid was
evaluated and the contribution of each was assessed
and compared with chemokine (C-X-C motif ) ligand 8
(CXCL8). Chemokine receptor expression on neutrophils
from blood or BAL ﬂuid of patients with ARDS was
analysed by ﬂow cytometry.
Results CCL2 and CCL7 were signiﬁcantly elevated in
BAL ﬂuid recovered from LPS-challenged volunteers and
patients with ARDS. BAL ﬂuid from patients with ARDS
was highly chemotactic for human neutrophils and
neutralising either CCL2 or CCL7 attenuated the
neutrophil chemotactic response. Moreover, CCL2 and
CCL7 synergised with CXCL8 to promote neutrophil
migration. Furthermore, neutrophils isolated from the
blood or BAL ﬂuid differentially regulated the cell surface
expression of chemokine (C-X-C motif ) receptor 1 and
C-C chemokine receptor type 2 during ARDS.
Conclusion This study highlights important
inﬂammatory chemokines involved in regulating
neutrophil migration, which may have potential value as
therapeutic targets for the treatment of ARDS.
INTRODUCTION
Acute respiratory distress syndrome (ARDS) is a
life-threatening condition that is still associated
with a high rate of mortality despite recent
improvements in mechanical ventilation strategies
and supportive care. ARDS is characterised by lung
oedema, presenting as diffuse bilateral lung opaci-
ties and hypoxaemia that does not arise from
cardiac failure or ﬂuid overload.1 ARDS can be
classiﬁed as mild, moderate or severe, depending
on the partial pressure of arterial oxygen to frac-
tion of inspired oxygen ratios (PaO2/FIO2). ARDS
remains a syndrome resulting from varied aetiolo-
gies and is associated with multiple pathologies, of
which diffuse alveolar damage remains the most
common pathognomonic feature.2
Disease onset is often rapid and progressive and
is usually the result of either a direct insult to the
lung, such as pneumonia, aspiration of gastric con-
tents or pulmonary contusion or the indirect insults
such as non-pulmonary sepsis, polytrauma or
transfusion-associated acute lung injury. ARDS is
further associated with acute inﬂammation3 and the
rapid accumulation of neutrophils in the lung inter-
stitium and alveolar space.4 In addition, neutrophil
counts remain higher in the bronchoalveolar lavage
(BAL) ﬂuid of non-survivors with ARDS compared
with survivors.5 The excessive accumulation of neu-
trophils in ARDS has therefore been directly impli-
cated in disease pathogenesis and poor clinical
outcome.6
The migration of neutrophils into inﬂamed lungs
is mediated by multiple factors, of which cell adhe-
sion molecules and chemokines are thought to be
the most important.7 The chemokine (C-X-C
motif) ligand 8 (CXCL8) (interleukin (IL)-8) is
considered to be the archetypal neutrophil chemo-
attractant. Indeed, the levels of CXCL8 have been
positively correlated with the number of neutro-
phils recovered from patients with ARDS8 and with
disease severity.9 10 However, several studies have
reported that other chemokines may be elevated in
ARDS.11 Furthermore, we have recently reported
Key messages
What is the key question?
▸ To what extent do the chemokine (C-C motif )
ligand (CCL)2 and CCL7 contribute to the
migratory activity of neutrophils during acute
respiratory distress syndrome (ARDS)?
What is the bottom line?
▸ Both CCL2 and CCL7 contribute to neutrophil
chemotaxis during ARDS by synergising with
chemokine (C-X-C motif ) ligand 8.
Why read on?
▸ Excessive neutrophil recruitment during ARDS is
associated with disease severity and poor
clinical outcome; therefore, a clearer
understanding of these pathomechanisms is
urgently needed.
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that neutrophil recruitment in the lung airspaces, in response to
lipopolysaccharide(LPS)-induced lung inﬂammation, is mediated
by the chemokine (C-C motif) ligand (CCL)2 and CCL7,12
while CCL7 regulates neutrophil recruitment in response to
acute infection with the bacterium Streptococcus pneumoniae.13
In this report we aim to gain a better understanding of the
potential roles of CCL2 and CCL7 in ARDS by focussing on
their contribution to neutrophil recruitment. To this end we
measured the levels of CCL2 and CCL7 in samples obtained
from a human LPS-challenged model of acute lung injury and
two separate cohorts of patients with ARDS. We investigated
the contribution of CCL2 and CCL7 to the neutrophil chemo-
tactic activity of human ARDS BAL ﬂuid and assessed the
chemotactic response of neutrophils to CCL2 and CCL7 in the
context of the classical neutrophil chemokine CXCL8. Finally,
we analysed the chemokine receptor expression on neutrophils
derived from the blood and BAL ﬂuid of patients with ARDS to
determine if the receptor expression patterns change during
neutrophil transmigration into the airspaces.
MATERIALS AND METHODS
Human LPS challenge and ARDS sample collection
Healthy subjects (age 25.8±5.5 years; mean±SD) were chal-
lenged with nebulised 0.9% saline or 50 μg LPS (Escherichia
coli serotype O26:B6; Sigma, UK) in sterile saline, as part of a
previously published study.14 BAL was performed 6 hours after
challenge according to standard guidelines and prepared for
analysis as previously described.14 Saline-challenged (n=5) and
LPS-challenged (n=25) BAL ﬂuid samples were used to measure
the protein levels of CCL2 and CCL7 by ELISA (R&D Systems)
according to the manufacturer’s instructions.
Mechanically ventilated patients in the intensive care unit of
the Royal Victoria Hospital, Belfast, Northern Ireland, were
diagnosed with ARDS according to the consensus conference
deﬁnition as previous described.15 Baseline BAL ﬂuid samples,
before administration of drug or placebo, from a randomised
clinical trial (The HARP Study) were used for this study in
order to measure CCL2 (n=18) and CCL7 (n=18) protein
levels.16 Samples were prepared as previously described.16 A
second cohort, again from two previously described, rando-
mised, placebo-controlled clinical trials (the BALTI and
VINDALOO trials),17 18 were used to assess CCL2 and CCL7
protein levels in the BAL ﬂuid from postoperative oesophagect-
omy patients who were at risk of developing ARDS, but did
not, compared with those who did develop ARDS (n=20 for
each, ARDS deﬁned as PaO2:FIO2 ratio of<300 mm Hg).
Random samples from both studies were used. Local institution
and research ethics committee approval was obtained. Written
informed consent from the legal representative of the patient or
retrospective informed consent was obtained from the patient, if
possible.
For ﬂow cytometry analysis, adult patients over the age of 18
with suspected or conﬁrmed community-acquired pneumonia
with ARDS who required mechanical ventilation were recruited.
ARDS was deﬁned as meeting the American-European consen-
sus deﬁnition of ARDS.15 Inclusion and exclusion criteria are
deﬁned in online supplementary table S1 and patient clinical
details are described in online supplementary table S2. Ethics
approval was obtained from the London-South East research
ethics committee (ref: 13/LO/274). Informed consent was
obtained from legal representatives of the subjects and retro-
spective informed consent from the individual where possible.
Bronchoscopy was performed on mechanically ventilated
patients via the endotracheal tube. BAL was performed in the
lobe that appeared to be most affected on chest radiograph or
CT. BAL was performed as previously described.14 Total cell
counts were obtained using a haemocytometer.
Neutrophil isolation
Neutrophils were isolated from the blood of healthy volunteers.
About 20 mL blood was layered onto 10 mL 6% dextran (from
leuconostoc spp, MR 45 000; Sigma-Aldrich) in sterile 0.9%
saline and 20 mL phosphate-buffered saline (PBS). The solution
was left to sediment for 45 min. The buffy coat layer was
removed and centrifuged at 300 g for 5 min in 50 mL PBS, the
leucocyte-rich layer was removed and resuspended in 55%
Percol (GE Healthcare). A Percol gradient was prepared from
81% and 67% Percol and the resuspended leucocytes were
layered on top (in 55% Percol). The Percol gradient was centri-
fuged for 30 min at 700 g. The neutrophil layer was removed
and washed in PBS followed by centrifugation at 300 g for
10 min. Neutrophils were resuspended in 1 mL double-distilled
H2O for 30 s and resuspended in 20 mL PBS. Cells were centri-
fuged and resuspended in RPMI-1640 (Sigma-Aldrich). Isolated
neutrophils had a purity of >98% (see online supplementary
ﬁgure S1).
Neutrophil chemotaxis assay
ChemoTX plates (Neuro Probe) were used throughout (3 mm
pores in a 96-well plate) employing 5×104 neutrophils per well
in RPMI-1640. Chemotaxis of isolated human neutrophils was
measured in response to human BAL ﬂuid (described above),
with or without 10 mg/mL anti-human CCL2 or CCL7 neutra-
lising antibody (anti-human CCL2 279-MC, R&D Systems,
anti-human CCL7 AF-282-NA, R&D Systems), 10 mg/mL anti-
human CXCL8 neutralising antibody (anti-human IL-8
AB-208-NA, R&D Systems) or 20 μg/mL polyclonal Ig control
(R&D Systems) diluted 1:1 in RPMI-1640. The concentration
of antibody used exceeded that required to neutralise the
amount of chemokine in human ARDS BAL ﬂuid (at least
10-fold excess; 10 μg/mL antibody has ND50 5–20 μg/mL che-
mokine). BAL ﬂuid was incubated for 20 min with each neutra-
lising antibody in the lower chamber, prior to the addition of
5×104 neutrophils per well onto the upper membrane. At least
18 BAL ﬂuid samples from different patients were used and
each sample was run in triplicate. Neutrophils from the blood
of multiple healthy human volunteers were used throughout.
Recombinant human CXCL8 (IL-8), CCL2 and CCL7
(Peprotech) were used at various concentrations, were resus-
pended in RPMI-1640 and were placed in the lower chamber of
the ChemoTX plate. Neutrophils were placed on the upper
membrane and incubated at 37°C in 5% CO2 for 1 hour.
Migrated neutrophils were counted using a haemocytometer
and the chemotactic index was calculated (number of migrated
neutrophils following treatment vs medium control).
Flow cytometry analysis
About 30 mL of red cell lysis buffer (Roche, UK) was added to
3 mL of blood for 15 min. About 20 mL of PBS was added and
sample was centrifuged at 300 g for 5 min. BAL ﬂuid cell pellets
were resuspended in 1 mL red cell lysis buffer for 10 min. Cells
were resuspended in 1 mL PBS. Non-speciﬁc binding was blocked
with 10% fetal bovine serum in PBS. Single-stained controls and
ﬂuorescence minus one controls were included. Neutrophils were
gated using anti-CD14 (Becton Dickinson (BD)), anti-CD16
(R&D Systems) and anti-human leucocyte antigen-D-related
(HLA-DR) (BD) antibodies (gating strategy is described in online
supplementary ﬁgure S2). Chemokine receptor expression was
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assessed following incubation with anti- chemokine (C-X-C
motif) receptor (CXCR)1 (BD), anti-CXCR2, anti-C-C chemo-
kine receptor (CCR)1, anti-CCR2 and anti-CCR3 antibodies (all
R&D Systems). Following 20 min incubation, samples were
washed twice with 100 mL of 1% bovine serum albumin in PBS
and centrifuged at 300 g for 3 min at each wash and the super-
natant discarded. Cells were resuspended in 100 mL of 4% para-
formaldehyde (PFA) and were kept at 4°C in the dark until
acquisition on a FACS Verse ﬂow cytometer (BD).
Statistical analysis
Statistical analysis was performed using one-way analysis of vari-
ance with Newman-Keuls post-hoc test. p Values are presented
within each ﬁgure.
RESULTS
CCL2 and CCL7 are elevated in ARDS BAL ﬂuid
We have previously reported that the chemokines CCL2 and
CCL7 are elevated in the lungs of mice challenged with either
LPS or infected with S. pneumoniae and that neutralising these
chemokines inhibits neutrophil accumulation in BAL ﬂuid.12 13
In order to translate these ﬁndings into the human disease
setting, we ﬁrst collected BAL ﬂuid from healthy volunteers
who were challenged with LPS (50 mg) or saline. The levels of
both CCL2 (ﬁgure 1A) and CCL7 (ﬁgure 1B) were increased in
the BAL ﬂuid isolated from LPS-challenged individuals.
Furthermore, patients with a clinical diagnosis of ARDS had ele-
vated levels of CCL2 (ﬁgure 1A) and CCL7 (ﬁgure 1B) in BAL
ﬂuid compared with normal controls and higher levels of these
chemokines compared with LPS-challenged volunteers. In com-
parison, the levels of CXCL8 in ARDS BAL ﬂuid previously
reported by Craig et al16 (2011) ranged between 40 and
9721 pg/mL (mean 3277, SD 3684). In a second, independent
cohort of patients with a clinical diagnosis of ARDS following
oesophagectomy, levels of CCL2 (ﬁgure 1C) and CCL7 (ﬁgure
1D) were increased compared with postoperative patients at
high risk of developing ARDS but remained free of clinical diag-
nosis. Collectively, these ﬁndings suggest that CCL2 and CCL7
may play a role in the pathogenesis of ARDS in humans.
CCL2 and CCL7 signiﬁcantly contribute to the chemotactic
potency of ARDS BAL ﬂuid
Having demonstrated that CCL2 and CCL7 are elevated in BAL
ﬂuid isolated from patients with ARDS, we next sought to eluci-
date whether CCL2 and CCL7 contribute to neutrophil recruit-
ment in ARDS. First, we demonstrated that ARDS BAL ﬂuid is
highly chemotactic for human neutrophils compared with BAL
ﬂuid from healthy volunteers (ﬁgure 2A). In order to determine
the contribution of CCL2 and CCL7 to the chemotactic activity
of ARDS BAL ﬂuid, we neutralised both chemokines using spe-
ciﬁc antibodies. Compared with the maximal chemotactic activ-
ity of ARDS BAL ﬂuid, neutralising the classical neutrophil
chemokine, CXCL8, signiﬁcantly decreased neutrophil chemo-
taxis (ﬁgure 2B, C). Neutralising either CCL2 (ﬁgure 2B) or
CCL7 (ﬁgure 2C) also decreased neutrophil chemotaxis towards
ARDS BAL ﬂuid, but a combination of either anti-CXCL8 plus
Figure 1 Plots showing th elevated bronchoalveolar lavage (BAL) ﬂuid levels of chemokine (C-C motif ) ligand (CCL)2 and CCL7 in a human model
of acute lung inﬂammation and in patients with acute respiratory distress syndrome (ARDS). Healthy volunteers were challenged with 0.6%
nebulised saline (n=5) or with 50 μg of nebulised lipopolysaccharide(LPS) (n=25) and BAL was performed 6 hours later. The levels of CCL2 (A) and
CCL7 (B) were measured in BAL ﬂuid recovered from saline and LPS-challenged volunteers by ELISA (right axis). BAL was also performed on patients
with a clinical diagnosis of ARDS and the levels of CCL2 (A) and CCL7 (B) were measured (n=18) in recovered ARDS BAL ﬂuid by ELISA (left axis).
BAL ﬂuid was also recovered from a second cohort of patients who underwent surgical oesophagectomy who were either at risk of developing ARDS
(n=20) or who went on to develop ARDS (n=20). The levels of CCL2 (C) and CCL7 (D) were measured in recovered BAL ﬂuid by ELISA. Power
calculations were based on previous studies with α=0.05; power=0.8; difference between means=1.5 (50% reduction); SD=1.6. Statistical analysis
was performed using one-way analysis of variance with Newman-Keuls post-hoc test.
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anti-CCL2 (ﬁgure 2B) or a combination of anti-CXCL8 plus
anti-CCL7 (ﬁgure 2C) caused a cumulative decrease in the neu-
trophil chemotactic response to ARDS BAL ﬂuid. Taken
together, these data suggest that CCL2 and CCL7 may contri-
bute to the recruitment of neutrophils in ARDS by synergising
with CXCL8.
CCL2 and CCL7 enhance neutrophil chemotaxis to CXCL8
We next compared the neutrophil chemotactic activity of CCL2
and CCL7 with that of CXCL8. Neutrophils migrated towards
CXCL8 in a concentration-dependent manner (ﬁgure 3A), with
maximal chemoattraction at 50 ng/mL. CCL2 (ﬁgure 3B) and
CCL7 (ﬁgure 3C) alone caused a small but non-signiﬁcant
amount of chemotaxis of neutrophils over a range of concentra-
tions. However, when combined with a suboptimal dose of
CXCL8 (5 ng/mL), both CCL2 (ﬁgure 3B) and CCL7 (ﬁgure
3C) signiﬁcantly increased neutrophil chemotaxis. The data
further suggest that CCL2 and CCL7 enhance neutrophil
chemotaxis by synergising with CXCL8.
BAL ﬂuid neutrophils from patients with ARDS modify their
chemokine receptor expression
We have previously demonstrated, in a mouse model of
LPS-induced acute lung inﬂammation, that neutrophils can alter
their expression of chemokine receptors when migrating into
inﬂamed lung.12 Therefore, in order to determine whether the
cell surface chemokine receptor expression on neutrophils
changes during neutrophil transmigration in ARDS, we exa-
mined whether the surface expression of CXCR1, CXCR2
(receptors for CXCL8), and CCR1, CCR2 and CCR3 (receptors
for CCL2 and CCL7) differed on neutrophils isolated from the
blood and BAL ﬂuid of patients with ARDS. The conventional
neutrophil chemokine receptors CXCR1 and CXCR2 were
highly expressed on neutrophils (CD16+, CD14−, HLA-DR−;
gating strategy for BAL ﬂuid and blood, see online supplemen-
tary ﬁgure S2) isolated from the blood of patients with ARDS
(ﬁgure 4A). In contrast, neutrophils isolated from the ARDS
BAL ﬂuid of patient with ARDS exhibited a signiﬁcant decrease
in cell surface CXCR1 expression relative to the levels expressed
Figure 2 Chemokine (C-X-C motif ) ligand 8 (CXCL8), chemokine (C-C motif ) ligand (CCL)2 and CCL7 contribute to the neutrophil chemotactic
activity of acute respiratory distress syndrome (ARDS) bronchoalveolar lavage ﬂuid (BALF). Human neutrophils were isolated from the blood of
healthy volunteers and chemotaxis was measured across 3 mm membranes (ChemoTX, NeuroProbe) in response to media alone, healthy volunteer
BALF (n=11) or BALF from patients with ARDS (n=18) (A). Neutrophil chemotaxis was measured as the chemotactic index (number of migrated
neutrophils following treatment vs medium control) after 1 hour (healthy BALF, left axis; ARDS BALF, right axis). Neutrophil chemotaxis towards
BALF obtained from patients with ARDS was measured in the presence of polyclonal Ig control (20 μg/mL), neutralising anti- CXCL8) (10 μg/mL),
anti-CCL2 (10 μg/mL) and a combination (10 μg/mL of each) of the two antibodies (B) or anti-CXCL8 (10 μg/mL), anti-CCL7 (10 μg/mL) and a
combination (10 μg/mL of each) of the two antibodies (C). Antibodies were incubated in the presence of ARDS BALF for 20 min prior to the addition
of isolated neutrophils. Differences in neutrophil chemotaxis between treatment groups were measured as the percentage of maximal chemotaxis to
ARDS BALF alone (n=18 ARDS BALF samples using neutrophils isolated from multiple healthy human volunteers). Statistical analysis was performed
using one-way analysis of variance with Newman-Keuls post-hoc test.
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by blood neutrophils (ﬁgure 4A). The expression of CXCR2 on
ARDS BAL ﬂuid neutrophils was more heterogeneous
(ﬁgure 4B), with no signiﬁcant alteration in expression levels.
The expression of the CCL2 and CCL7 chemokine receptors
CCR1, CCR2 and CCR3 on the blood neutrophils of patients
with ARDS were low compared with that of CXCR1 and
CXCR2 (ﬁgure 4C–E). The expression of CCR1 and CCR3 on
ARDS BAL ﬂuid neutrophils of patients with ARDS was not sig-
niﬁcantly different compared with the blood neutrophils of
patients with ARDS (ﬁgure 4C, E). However, the expression of
CCR2 was signiﬁcantly elevated on neutrophils isolated from
ARDS BAL ﬂuid (ﬁgure 4D) relative to the expression levels
measured on blood neutrophils (the mean ﬂuorescent intensity
for each chemokine receptor in the blood and BAL ﬂuid is pre-
sented in online supplementary ﬁgure S3). Taken together, these
data show that neutrophil chemokine receptor expression is
plastic and changes during neutrophil transmigration from the
blood to the airspaces during ARDS and these data further
show that these neutrophils may gain responsiveness to CCL2
and CCL7 by expressing CCR2.
DISCUSSION
In the present study, we aimed to determine the role of CCL2
and CCL7 in inﬂuencing neutrophil chemotaxis in the context
of ARDS. We have previously demonstrated that CCL2 and
CCL7 are elevated in a mouse model of LPS-induced acute lung
inﬂammation12 and a mouse model of S. pneumoniae infec-
tion.13 Furthermore, neutralisation of either CCL2 or CCL7
reduced the number of neutrophils isolated from the BAL ﬂuid
of LPS-treated mice, while neutralisation of CCL7 reduced the
neutrophil numbers following pneumococcal infection.
However, the contribution of these chemokines in the setting of
human ARDS is not known.
ARDS is associated with an increase in several proinﬂamma-
tory cytokines, chemokines and growth factors. Of note, IL-1β,
tumour necrosis factor, IL-6 and CXCL8 are considered to be
central mediators of the inﬂammatory immune response during
ARDS pathogenesis.19 Activation of tissue-resident alveolar
macrophages, alveolar epithelium and the endothelium estab-
lishes a lung environment conducive to the recruitment of
inﬂammatory cells in the airspace.6 Neutrophils comprise the
Figure 3 Human neutrophils migrate toward recombinant chemokine (C-X-C motif ) ligand 8 (CXCL8), chemokine (C-C motif ) ligand (CCL)2 and
CCL7. Human neutrophils were isolated from the blood of healthy volunteers and chemotaxis was measured across 3 mm membranes (ChemoTX,
NeuroProbe) in response to recombinant human CXCL8, CCL2 and CCL7 (A), over a range of concentrations as stated. Neutrophil chemotaxis was
also measured in response to a suboptimal concentration of recombinant human CXCL8 (5 ng/mL) in combination with recombinant human CCL2
(B) or recombinant human CCL7 (C) across a range of concentrations as stated (n=3 independent experiments using different healthy volunteer
donors). Neutrophil chemotaxis was measured as the chemotactic index (number of migrated neutrophils following treatment vs medium control)
after 1 hour. Statistical analysis was performed using one-way analysis of variance with Newman-Keuls post-hoc test.
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majority of cells recruited into the lung and although they are
important for the clearance of pathogens, they are thought to
contribute to the disruption of the epithelial-endothelial barrier
in ARDS.20 The result of a damaged alveolar-endothelial unit is
the leakage of protein-rich ﬂuid into the airspace, which in turn
compromises gaseous exchange and promotes respiratory
failure.
The chemokine CXCL8 is considered to be the archetypal
neutrophil chemoattractant and levels of CXCL8 have been
directly associated with the number of neutrophils recruited
into the inﬂamed lung during ARDS, as well as with disease
severity and poor clinical outcome.21–23 Although CCL2 has
previously been shown to be elevated in BAL ﬂuid of patients
with ARDS,11 its speciﬁc role in mediating neutrophil migration
in this disease setting has not been comprehensively explored.
Furthermore, the closely related chemokine family member,
CCL7, has largely been overlooked in inﬂammatory lung dis-
eases. CCL2 and CCL7 are conventionally considered to
mediate the recruitment of monocytes and macrophages into
sites of inﬂammation in response to various inﬂammatory
insults,24 including LPS,25 and the bacterium Listeria monocyto-
genes.26 In humans, CCL2 and CCL7 have been shown to dif-
ferentially induce the chemotaxis of macrophages, with CCL7
being the only chemokine to induce the migration of M1 and
M2 macrophages.27 More recently, it has been demonstrated
that CCL2 and CCL7 can also function as chemoattractants for
mouse28 29 and human neutrophils.30 We now show, for the
ﬁrst time, that CCL2 and CCL7 contribute to the neutrophil
chemotactic activity of ARDS BAL ﬂuid and that they synergise
with CXCL8 to promote neutrophil chemotaxis.
Even though they are closely related chemokines, CCL2 and
CCL7 differ in their biophysical characteristics. While CCL2 is
a ligand restricted to the CCR2 receptor,31 CCL7 is more pro-
miscuous and can bind and signal via CCR1, CCR2 and
CCR332 and may therefore be able to inﬂuence the migratory
capacity of multiple cell types compared with CCL2. In add-
ition, CCL7 is able to bind to glycosaminoglycan (GAG) poly-
saccharides with higher afﬁnity, so that CCL7 may form a more
robust chemotactic gradient compared with CCL2.33 This addi-
tional GAG-binding property of CCL7 may also account for
lower amounts of detectable unbound CCL7 in body ﬂuids
compared with CCL2. These are important considerations
which need to be taken into account when designing new thera-
peutics that target chemokine family members.
In both chemokine neutralisation studies and in chemotaxis
assays using recombinant human chemokines, we demonstrated
that a level of synergy exists between CXCL8 and CCL2 or
CCL7 in promoting neutrophil migration. It has previously
been shown that CCL7 can synergise with CXCL6, in a mouse
model of peritoneal inﬂammation34 and with CXCL10 in
mouse models of acid-induced lung injury and inﬂuenza infec-
tion.29 Certain chemokines are also able to act cooperatively by
forming heterodimers. For example, CCL5 and CXCL4 hetero-
dimers are elevated in ARDS and in mouse models of lung
injury, while destabilising these complexes reduced sepsis and
LPS-induced lung injury in mice.35 Although CXCL8, and most
other chemokines, can form homodimers and even tetramers,
the different three-dimensional conﬁguration of CXC-
chemokines compared with CC-chemokines makes heterodimer
formation between family members more likely than mixed
Figure 4 Neutrophils differentially regulate chemokine receptors during acute respiratory distress syndrome (ARDS). Bronchoalveolar lavage ﬂuid
(BALF) and blood was recovered from patients with a clinical diagnosis of ARDS (patient details in online supplementary table S2). Flow cytometry
analysis of neutrophils was performed by gating on CD16+, CD14−, human leucocyte antigen-D-related (HLA-DR)− leucocyte populations. The
neutrophil population was further veriﬁed by FSC and SSC properties (details in online supplementary ﬁgure S2). The expression of chemokine
(C-X-C motif ) receptor (CXCR)1 (A), CXCR2 (B), C-C chemokine receptor (CCR)1 (C), CCR2 (D) and CCR3 (E) on neutrophils from the blood of
patients with ARDS was compared with neutrophils from the BALF of matching patients with ARDS (n=10). Data are represented as the ratio of
mean ﬂuorescent intensity (MFI) of each chemokine receptor expressed on BALF neutrophils versus blood neutrophils (direct measurements of MFI
are presented in online supplementary ﬁgure S3). Statistical analysis was performed using one-way analysis of variance with Newman-Keuls
post-hoc test. FSC, forward scatter; SSC, side scatter.
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CXC-CC heterodimers.36 For example, CXCL8 readily forms a
heterodimer with CXCL4 (platelet factor 4), while CCL2 can
form heterodimers with CCL5 and CCL8. However, there is
currently no direct evidence that CXCL8 can form heterodimers
with either CCL2 or CCL7. In addition, CCL7 is considered to
function as an obligate monomer and therefore highly unlikely
to dimerise under these conditions.33 Furthermore, dimerisation
is largely thought to increase the stability of chemokines in
physiological ﬂuids but is independent of receptor activation.37
The synergistic effect between CXCL8 and CCL2 or CCL7 is
therefore most likely due to increased receptor occupancy on
neutrophils, which in turn accounts for heightened chemotaxis
towards multiple chemokines. Previous studies using recombin-
ant chemokines reported that both CCL2 and CCL7 can syner-
gise with CXCL8 to enhance neutrophil migration, with CCL7
being more effective than CCL2.38 39 Our data conﬁrm the
synergistic effect between these chemokines and highlight its
potential importance in the ARDS disease setting. Human neu-
trophils isolated from the BAL ﬂuid of patients with COPD
have also been reported to express higher levels of CCR1,
CCR2 and CCR3 and CCL2, CCL3, CCL4 and CCL11 were
able to induce chemotaxis of neutrophils isolated from BAL
ﬂuid of patients with COPD.30 This and our current study
therefore suggest that neutrophils are capable of responding to a
number of CC and CXC chemokines other than CXCL8 and its
closely related family members.
We previously demonstrated that in mouse models of acute
lung injury, neutrophils differentially express CXCR and CCR
chemokine receptors on their cell surface depending on the
tissue micro-compartment in which they reside.12 In order to
determine if this is also the case in human ARDS, we analysed
neutrophils from the blood and BAL ﬂuid of patients with
ARDS. Compared with blood neutrophils, BAL ﬂuid neutrophils
expressed signiﬁcantly lower levels of CXCR1 but higher levels
of CCR2, suggesting that human neutrophils can also gain
responsiveness to different chemokine subsets depending on the
tissue microenvironment in which they reside. The increased
expression of CCR2 on ARDS BAL ﬂuid neutrophils further
suggests that neutrophils are capable of responding to CCL2
and CCL7 within airspaces in this disease setting, although the
factors that regulate CCR2 expression on neutrophils will need
to be fully explored in the future.
Our study has some limitations in that although we demon-
strated that CCL2 and CCL7 levels are elevated in ARDS, we
would have ideally also included studies using a comparator
control group of mechanically ventilated patients without
ARDS. To address this, we analysed a separate cohort of oeso-
phagectomy patients with and without ARDS and demonstrated
that CCL2 and CCL7 levels are signiﬁcantly increased in
patients who went on to develop ARDS.
In conclusion, our data indicate that CCL2 and CCL7 levels
are elevated in BAL ﬂuid samples from patients with ARDS and
that these chemokines contribute to the chemotactic activity of
ARDS BAL ﬂuid by synergising with the conventional neutro-
phil chemoattractant, CXCL8. Furthermore, neutrophils differ-
entially regulate the expression of CXCR1 and CCR2 when
migrating into the bronchoalveolar compartment, thereby enab-
ling them to gain responsiveness to different chemokine subsets
depending on the tissue microenvironment in which they reside.
Our neutrophil receptor expression studies further highlight
that there is patient heterogeneity in terms of expression pat-
terns. A clearer understanding of patient heterogeneity in ARDS
is critical for the successful design and implementation of both
new therapeutics and clinical trials in this disease setting.
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